N
Neurogene
Focused on developing life-changing genetic medicines for patients and their families affected by rare, devastating neurological diseases
About Neurogene
Neurogene is a biotechnology company dedicated to developing genetic medicines aimed at treating rare and devastating neurological diseases. The company focuses on creating life-changing therapies for patients and their families who are affected by these conditions. Neurogene operates in the healthcare and biotechnology market, primarily serving patients with rare neurological disorders, a segment that often lacks effective treatment options.
The business model of Neurogene revolves around research and development (R&D) of gene therapy candidates. The company invests heavily in scientific research to identify and develop potential treatments, which are then tested through clinical trials. Revenue is generated through partnerships, grants, and potentially through the commercialization of successful therapies.
Neurogene's headquarters are located in New York, with a manufacturing facility in Houston, Texas. The company is led by a senior leadership team with extensive experience in drug development and a strong commitment to their mission.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2018
- Headquarters
- New York City, United States
- Listing
- IPO 2023
- Employees
- 136
- Open positions
- 15
- Dealroom signal
- 91.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jul 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2026 | $0 | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT VCOther financing | Nov 2024 | $200M | — | Casdin Capital · EcoR1 Capital · Great Point Partners · Redmile Group | ↗ |
Growth signals
Latest recorded traffic for Neurogene is 7.6K monthly website visits, down 7.3% over the last three months. Neurogene's team grew 20.4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Redmile Group
EcoR1 Capital
Cormorant Asset Management
Samsara BioCapital
Casdin Capital
Ascendant Capital
BlackRock
Alexandria Venture Investments
Janus Henderson Investors- APArrowMark Partners
Avidity Partners
Other known investors4 additional known investors
Great Point Partners
Commodore Capital
RTW Investments
University of Washington
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neurogene on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neurogene’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.